The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred ...

Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...

Novo Nordisk A/S (NYSE: NVO) is one of the best beginner stocks to buy, according to analysts. On September 17, Berenberg ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Pharmaceutical companies are racing to develop a GLP-1 weight-loss drug in pill form. Novo Nordisk says its oral semaglutide pill led to "significant weight loss" in a trial.

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Over the last six years, three GLP-1 drugs have been approved for children aged 10 and older with type 2 diabetes. | Over the ...

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

Inspire Medical Systems, Inc. (NYSE:INSP), a leader in minimally invasive devices for obstructive sleep apnea (OSA), reported ...

“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

Makers of GLP-1 drugs, including Novo Nordisk, Eli Lilly and others, are close to releasing daily pills to help shed pounds ...